|
시장보고서
상품코드
1986641
CAR-T 세포치료 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 질환별, 용도별, 지역별 및 부문별 예측(2026-2033년)CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
CAR-T 세포치료 시장 요약
세계의 CAR-T 세포치료 시장 규모는 2025년에 58억 2,000만 달러로 추계되며, 2033년까지 223억 6,000만 달러에 달할 것으로 예측됩니다.
2026-2033년 CAGR 18.06%로 성장할 것으로 예상됩니다. 시장 성장은 암 환자 수 증가, 개인 맞춤형 세포 치료의 보급, 유전자 편집 기술의 발전, 그리고 지원적인 규제에 의해 주도되고 있습니다.
암 부담 증가
암, 특히 백혈병, 림프종, 다발성골수종 등 혈액암의 유병률 증가가 CAR-T 세포치료제 산업을 주도하고 있습니다. 기존 치료법으로는 장기적인 관해에 도달하지 못하는 경우가 많지만, 환자의 T세포를 변형시켜 암을 표적으로 삼는 CAR-T 세포 치료는 더 높은 효능과 지속적인 반응을 가져옵니다. 전 세계에서 암 발병률이 증가함에 따라 이러한 첨단 개인 맞춤형 치료법에 대한 수요가 증가하고 있습니다.
진행성 또는 치료 저항성 혈액암에 대한 선택지가 제한적이라는 점이 CAR-T 세포치료제 시장의 성장을 지원하고 있습니다. 이러한 치료법은 중요한 미충족 수요에 대응하고 있으며, 의료진과 환자들 사이에서 인지도가 높아지면서 보급이 가속화되고 있습니다. 다른 유형의 암과 고형암에 대한 임상 시험이 확대됨에 따라 수요는 더욱 증가할 것으로 예상되며, CAR-T 세포 치료는 종양학의 핵심 초점이 될 것입니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 시장 변수, 동향 및 범위
제4장 제품 사업 분석
제5장 질환 적응증별 사업 분석
제6장 최종 용도별 사업 분석
제7장 지역별 사업 분석
제8장 경쟁 구도
KSA 26.04.28CAR T-cell Therapy Market Summary
The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.
Rising Cancer Burden
The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient's T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.
Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.
Global CAR T-cell Therapy Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Abecma (idecabtagene vicleucel)
- Breyanzi (lisocabtagene maraleucel)
- Carvykti (ciltacabtagene autoleucel)
- Kymriah (tisagenlecleucel)
- Tecartus (brexucabtagene autoleucel)
- Yescarta (axicabtagene ciloleucel)
- Others
- Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Leukemia
- Lymphoma
- Multiple Myeloma
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Cancer Treatment Centers
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Rest of World
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Product Segment
- 1.1.1.2. Disease Indication Segment
- 1.1.1.3. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objective
- 1.4.1. Objective 1
- 1.4.2. Objective2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis:
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising cancer burden
- 3.2.1.2. Personalized treatment advantage
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Regulatory complexity
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
Chapter 4. Product Business Analysis
- 4.1. Product Segment Dashboard
- 4.2. CAR T-cell Therapy Market: Product Movement Analysis
- 4.3. Abecma (idecabtagene vicleucel)
- 4.3.1. Abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
- 4.4. Breyanzi (lisocabtagene maraleucel)
- 4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
- 4.5. Carvykti (ciltacabtagene autoleucel)
- 4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
- 4.6. Kymriah (tisagenlecleucel)
- 4.6.1. Kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
- 4.7. Tecartus (brexucabtagene autoleucel)
- 4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
- 4.8. Yescarta (axicabtagene ciloleucel)
- 4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
- 4.9. Others
- 4.9.1. Others market, 2021 - 2033 (USD Million)
Chapter 5. Disease Indication Business Analysis
- 5.1. Disease Indication Segment Dashboard
- 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
- 5.3. Leukemia
- 5.3.1. Leukemia market, 2021 - 2033 (USD Million)
- 5.4. Lymphoma
- 5.4.1. Lymphoma market, 2021 - 2033 (USD Million)
- 5.5. Multiple Myeloma
- 5.5.1. Multiple myeloma market, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. CAR T-cell Therapy Market: End Use Movement Analysis
- 6.3. Hospitals
- 6.3.1. Hospitals market, 2021 - 2033 (USD Million)
- 6.4. Cancer treatment centers
- 6.4.1. Cancer treatment centers market, 2021 - 2033 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
- 7.2. North America
- 7.2.1. North America CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Competitive Scenario
- 7.2.2.3. Regulatory Framework
- 7.2.2.4. U.S. CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Competitive Scenario
- 7.2.3.3. Regulatory Framework
- 7.2.3.4. Canada CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.3.2. UK
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. UK CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Germany CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Japan CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. China CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.5. Rest of World
- 7.5.1. Rest of World CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Position Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. Bristol-Myers Squibb Company
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Novartis AG
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Gilead Sciences, Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Johnson & Johnson Services, Inc.
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. bluebird bio, Inc.
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Merck & Co., Inc.
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Sangamo Therapeutics
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Sorrento Therapeutics, Inc.
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. GSK plc.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.1. Bristol-Myers Squibb Company
